OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NSCI60

Nanalysis Scientific Corp

Advanced Medical Equipment & TechnologyVerified

Nanalysis Scientific Corp has a liquidity risk as indicated by a current ratio of 0.97, suggesting that its current assets are slightly less than its current liabilities. The company's liquidity position is further challenged by a negative net cash position after subtracting total debt, which is a key flag in its risk assessment. The company's debt-to-equity ratio of 1.31 indicates a moderate level of leverage, with long-term debt accounting for a significant portion of its liabilities. The company's profitability is weak, with a negative return on equity of -42.16% and a return on assets of -14.73%. These figures are below the industry norms for the Advanced Medical Equipment & Technology sector, which typically exhibit positive returns. The operating loss of $5.67 million and a net loss of $5.66 million further underscore the company's financial challenges. The company's revenue is split between two segments: Scientific Equipment and Security Services. The Scientific Equipment segment is the primary source of innovation and product development, while the Security Services segment is focused on providing maintenance and installation services for security equipment in Canadian airports. The geographic exposure is primarily within Canada, with a concentration in the security services market. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. However, the operating cash flow of $3.45 million suggests some operational resilience, although the free cash flow is negative at -$4.12 million, indicating that the company is not generating sufficient cash to fund its operations and capital expenditures. The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, suggesting that the company may need to seek additional financing to meet its obligations. The dilution risk is low, indicating that the company is not expected to issue a significant number of new shares in the near term. Recent events and filings do not provide specific details on new product launches or strategic initiatives. However, the company's focus on airport security equipment maintenance in Canada suggests a stable, albeit niche, market presence. The company's capital expenditure of -$1.88 million indicates a reduction in investment in new assets, which may be a strategic move to conserve cash.

30-day price · NSCI(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyNanalysis Scientific Corp
TickerNSCI.V
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Nanalysis Scientific Corp is a global manufacturer and seller of compact magnetic resonance imaging (MRI) and spectroscopy products, generating revenue primarily through the Scientific Equipment segment, which develops and sells MR products for various applications, and the Security Services segment, which provides maintenance and installation services for security equipment in Canadian airports.

Classification. Nanalysis Scientific Corp is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

Nanalysis Scientific Corp has a liquidity risk as indicated by a current ratio of 0.97, suggesting that its current assets are slightly less than its current liabilities. The company's liquidity position is further challenged by a negative net cash position after subtracting total debt, which is a key flag in its risk assessment. The company's debt-to-equity ratio of 1.31 indicates a moderate level of leverage, with long-term debt accounting for a significant portion of its liabilities. The company's profitability is weak, with a negative return on equity of -42.16% and a return on assets of -14.73%. These figures are below the industry norms for the Advanced Medical Equipment & Technology sector, which typically exhibit positive returns. The operating loss of $5.67 million and a net loss of $5.66 million further underscore the company's financial challenges. The company's revenue is split between two segments: Scientific Equipment and Security Services. The Scientific Equipment segment is the primary source of innovation and product development, while the Security Services segment is focused on providing maintenance and installation services for security equipment in Canadian airports. The geographic exposure is primarily within Canada, with a concentration in the security services market. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. However, the operating cash flow of $3.45 million suggests some operational resilience, although the free cash flow is negative at -$4.12 million, indicating that the company is not generating sufficient cash to fund its operations and capital expenditures. The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, suggesting that the company may need to seek additional financing to meet its obligations. The dilution risk is low, indicating that the company is not expected to issue a significant number of new shares in the near term. Recent events and filings do not provide specific details on new product launches or strategic initiatives. However, the company's focus on airport security equipment maintenance in Canada suggests a stable, albeit niche, market presence. The company's capital expenditure of -$1.88 million indicates a reduction in investment in new assets, which may be a strategic move to conserve cash.
Key takeaways
  • Nanalysis Scientific Corp operates in the Advanced Medical Equipment & Technology industry with a primary focus on compact MRI and spectroscopy products.
  • The company faces liquidity challenges, as indicated by a current ratio of 0.97 and a negative net cash position after subtracting total debt.
  • Profitability is weak, with a negative return on equity and return on assets, and the company reported an operating and net loss.
  • The company's revenue is concentrated in two segments, with a significant portion derived from security services in Canadian airports.
  • The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year.
  • The company has a low dilution risk, suggesting that it is not expected to issue a significant number of new shares in the near term.
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCAD
Revenue$40.1M
Gross profit$10.0M
Operating income-$5.7M
Net income-$5.7M
R&D
SG&A
D&A
SBC
Operating cash flow$3.5M
CapEx-$1.9M
Free cash flow-$4.1M
Total assets$38.4M
Total liabilities$25.0M
Total equity$13.4M
Cash & equivalents
Long-term debt$17.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$13.4M
Net cash-$17.6M
Current ratio1.0
Debt/Equity1.3
ROA-14.7%
ROE-42.2%
Cash conversion-61.0%
CapEx/Revenue-4.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 3 companies
MetricNSCIActivity
Op margin-14.1%19.4% medp25 17.8% · p75 22.0%bottom quartile
Net margin-14.1%17.7% medp25 16.4% · p75 19.0%bottom quartile
Gross margin24.8%73.5% medp25 71.3% · p75 75.8%bottom quartile
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue-4.7%4.3% medp25 3.9% · p75 4.3%bottom quartile
Debt / equity131.0%41.5% medp25 29.2% · p75 51.3%top quartile
Observations
IR observations
Mean price target0.50 CAD
Median price target0.50 CAD
High price target0.50 CAD
Low price target0.50 CAD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.00 CAD
Last actual EPS-0.05 CAD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 20:11 UTC#db5bf7d9
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 20:13 UTCJob: f35b0c69